Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 24

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 24
---
 carefully read both this prospectus and any prospectus supplement together with the additional information described
under “Where You Can Find More Information” before buying any securities in this offering.

The terms “INmune Bio,”
the “Company,” “we,” “our,” or “us,” in this prospectus refer to INmune Bio Inc. and its
wholly-owned subsidiaries, unless the context suggests otherwise.

<div align='center'>1

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and the documents
and information incorporated by reference in this prospectus include forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the
Exchange Act. These statements are based on our management’s beliefs and assumptions and on information currently available to our
management. All statements, other than statements of historical fact, included regarding our strategy, future operations, financial position,
future revenues, projected costs, plans, prospects and objectives are forward-looking statements. Words such as “expect,”
“anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,”
“think,” “may,” “could,” “will,” “would,” “should,” “continue,”
“potential,” “likely,” “opportunity” and similar expressions or variations of such words are intended
to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements. Examples of our forward-looking
statements include:

| ● | our ability to raise funds for general corporate purposes              
 and operations, including our research activities and clinical trials; |

| ● | our ability to recruit qualified management and technical 
 personnel;                                                |

| ● | the success of our clinical trials; |

| ● | our ability to obtain and maintain required regulatory approvals 
 for our trials;                                                  |

| ● | our expectations regarding the use of our existing cash and 
 the expected net proceeds of this offering;                 |

| ● | the other factors discussed in the “Risk Factors” 
 section and elsewhere in this prospectus.         |

Because forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control,
you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may